MorphoSys AG

Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab

Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million

Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process

Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023